Skip to main content
. 2024 Oct 27;114(1):4–16. doi: 10.1111/ejh.14335

FIGURE 1.

FIGURE 1

Key differences between bispecific antibodies and CAR T‐cell therapy in the treatment of relapsed/refractory follicular lymphoma.